跳转至内容
Merck
CN

Y0001510

Lactulose for peak identification

European Pharmacopoeia (EP) Reference Standard

别名:

Lactulose, 4-O-β-D-Galactopyranosyl-D-fructofuranose, 4-O-β-D-Galactopyranosyl-D-fructose

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C12H22O11
化学文摘社编号:
分子量:
342.30
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
93773
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Lactulose for peak identification, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12+/m1/s1

SMILES string

OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O

InChI key

JCQLYHFGKNRPGE-WJONTELPSA-N

grade

pharmaceutical primary standard

API family

lactulose

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

Application

Lactulose for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain.
Stephen E Congly et al.
The American journal of gastroenterology, 109(4), 598-598 (2014-04-05)
Parmjit S Panesar et al.
Biotechnology advances, 29(6), 940-948 (2011-08-23)
Lactulose a "bifidus factor" is composed of galactose and fructose, which can be produced by the isomerization of lactose. It is a prebiotic carbohydrate which stimulates the growth of health-promoting bacteria in the gastrointestinal tract, such as bifidobacteria and lactobacilli
Srinivasan Dasarathy
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 22 Suppl 2, S50-S53 (2004-03-18)
The pathogenesis of hepatic encephalopathy is mediated to a large extent by ammonia, mainly derived from the gut. Both bacterial and nonbacterial mechanisms of ammoniagenesis have been shown, but ammoniagenesis mediated by colonic bacteria is probably of clinical significance. The
Heather Lee-Robichaud et al.
The Cochrane database of systematic reviews, (7)(7), CD007570-CD007570 (2010-07-09)
Constipation is a common clinical problem. Lactulose and Polyethylene Glycol (PEG) are both commonly used osmotic laxatives that have been shown to be effective and safe treatments for chronic constipation. However, there is no definitive data as to which provides
Lactulose in clinical use.
J Ray et al.
Tropical gastroenterology : official journal of the Digestive Diseases Foundation, 17(2), 12-14 (1996-04-01)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持